HK1223559A1 - 用於促性腺激素的配方 - Google Patents

用於促性腺激素的配方 Download PDF

Info

Publication number
HK1223559A1
HK1223559A1 HK16111891.9A HK16111891A HK1223559A1 HK 1223559 A1 HK1223559 A1 HK 1223559A1 HK 16111891 A HK16111891 A HK 16111891A HK 1223559 A1 HK1223559 A1 HK 1223559A1
Authority
HK
Hong Kong
Prior art keywords
gonadotropins
formulation
fragmentation
provides
dose form
Prior art date
Application number
HK16111891.9A
Other languages
English (en)
Chinese (zh)
Inventor
Chintan Patel
Mukesh MAHAJAN
Sanjay Bandyopadhyay
Sanjeev Kumar Mendiratta
Bhatt CHANDRESH
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52684607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1223559(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of HK1223559A1 publication Critical patent/HK1223559A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16111891.9A 2013-11-12 2014-10-31 用於促性腺激素的配方 HK1223559A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3559/MUM/2013 2013-11-12
IN3559MU2013 IN2013MU03559A (OSRAM) 2013-11-12 2014-10-31
PCT/IN2014/000691 WO2015075743A1 (en) 2013-11-12 2014-10-31 Formulation for gonadotropins

Publications (1)

Publication Number Publication Date
HK1223559A1 true HK1223559A1 (zh) 2017-08-04

Family

ID=52684607

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111891.9A HK1223559A1 (zh) 2013-11-12 2014-10-31 用於促性腺激素的配方

Country Status (21)

Country Link
US (1) US20160250295A1 (OSRAM)
EP (1) EP3068374A1 (OSRAM)
JP (1) JP6166470B2 (OSRAM)
KR (1) KR101699677B1 (OSRAM)
CN (1) CN105658201A (OSRAM)
AP (1) AP2016009159A0 (OSRAM)
AR (1) AR098386A1 (OSRAM)
AU (1) AU2014351326B2 (OSRAM)
CA (1) CA2928311A1 (OSRAM)
CL (1) CL2016000944A1 (OSRAM)
EA (1) EA201690626A1 (OSRAM)
HK (1) HK1223559A1 (OSRAM)
IL (1) IL244986A (OSRAM)
IN (1) IN2013MU03559A (OSRAM)
MX (1) MX356383B (OSRAM)
NZ (1) NZ718960A (OSRAM)
PH (1) PH12016500738A1 (OSRAM)
SG (1) SG11201603142YA (OSRAM)
TW (1) TWI579003B (OSRAM)
WO (1) WO2015075743A1 (OSRAM)
ZA (1) ZA201602718B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2599031C1 (ru) * 2015-08-11 2016-10-10 Общество с ограниченной ответственностью "АйВиФарма" Водная композиция рекомбинантного фолликулостимулирующего гормона человека (варианты)
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
RU2633079C2 (ru) * 2016-06-21 2017-10-11 Федеральное государственное бюджетное научное учреждение "Центр экспериментальной эмбриологии и репродуктивных биотехнологий" (ФГБНУ ЦЭЭРБ) Фармацевтическая композиция с пролонгированным действием гонадотропинов для проведения индукции суперовуляции у самок млекопитающих
CN112451652A (zh) * 2020-12-07 2021-03-09 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液
CN115634284B (zh) * 2022-10-31 2025-02-11 景泽生物医药(合肥)股份有限公司 一种促性腺激素冻干制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518235B (en) 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
AU2004226666B9 (en) * 2003-04-02 2010-04-08 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
KR101105871B1 (ko) 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
PT2049148T (pt) * 2006-07-06 2016-12-30 Daewoong Co Ltd Formulação líquida estável da hormona do crescimento humana
US8329649B2 (en) * 2008-11-04 2012-12-11 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone and histidine
IT1395957B1 (it) * 2009-05-19 2012-11-02 Pharmaguida S R L Uso di una combinazione di d-aspartato e l-aspartato per il trattamento della infertilita' maschile.
WO2011099036A2 (en) * 2010-02-12 2011-08-18 Intas Biopharmaceuticals Limited Liquid formulation of follicle stimulating hormone
WO2011108010A2 (en) 2010-03-05 2011-09-09 Intas Biopharmaceuticals Limited A thermostable liquid formulation of gonadotropins
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US20130121961A1 (en) * 2011-11-11 2013-05-16 The Johns Hopkins University Treatment modalities to prevent or treat loss of cardiovascular function in aging humans

Also Published As

Publication number Publication date
WO2015075743A1 (en) 2015-05-28
AP2016009159A0 (en) 2016-04-30
CN105658201A (zh) 2016-06-08
KR20160048227A (ko) 2016-05-03
TW201529097A (zh) 2015-08-01
AR098386A1 (es) 2016-05-26
EP3068374A1 (en) 2016-09-21
IN2013MU03559A (OSRAM) 2015-07-24
JP2016534061A (ja) 2016-11-04
MX356383B (es) 2018-05-24
AU2014351326B2 (en) 2017-08-31
CA2928311A1 (en) 2015-05-28
CL2016000944A1 (es) 2016-11-11
TWI579003B (zh) 2017-04-21
SG11201603142YA (en) 2016-05-30
EA201690626A1 (ru) 2016-09-30
IL244986A0 (en) 2016-05-31
US20160250295A1 (en) 2016-09-01
KR101699677B1 (ko) 2017-01-24
ZA201602718B (en) 2017-06-28
JP6166470B2 (ja) 2017-07-19
PH12016500738A1 (en) 2016-05-30
IL244986A (en) 2016-11-30
NZ718960A (en) 2017-06-30
MX2016005154A (es) 2016-08-17
AU2014351326A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
WO2015038811A3 (en) Liquid protein formulations containing ionic liquids
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
PH12016500586A1 (en) Stabilized efinaconazole compositions
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
PH12016500738A1 (en) Formulation for gonadotropins
PH12015501620A1 (en) Pharmaceutical composition with improved bioavailability
NZ712270A (en) Pharmaceutical composition of s-ketamine hydrochloride
GEP201706734B (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
WO2012151247A3 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
IN2015KN00005A (OSRAM)
PH12015501753B1 (en) Enhanced stability of novel liquid compositions
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
EP4414376A3 (en) Novel depsipeptide and uses thereof
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
NZ702342A (en) Pharmaceutical formulation
WO2015089321A3 (en) Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
WO2018105941A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물
WO2014039074A3 (en) Therapeutic compositions and related methods
BR112015022196A2 (pt) composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos
EA201691355A1 (ru) Напитки с устойчивым вкусом
WO2014197536A3 (en) Novel beta lactams as modulators of glutamate uptake and methods for use thereof